PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
Top Cited Papers
- 30 April 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 179 (4), 1587-1592
- https://doi.org/10.1016/j.juro.2007.11.038
Abstract
A urinary assay for PCA3, an mRNA that is highly over expressed in prostate cancer cells, has shown usefulness as a diagnostic test for this common malignancy. We further characterized PCA3 performance in different groups of men and determined whether the PCA3 score could synergize with other clinical information to predict biopsy outcome. Prospectively urine was collected following standardized digital rectal examination in 570 men immediately before prostate biopsy. Urinary PCA3 mRNA levels were quantified and then normalized to the amount of prostate derived RNA to generate a PCA3 score. The percent of biopsy positive men identified increased directly with the PCA3 score. PCA3 assay performance was equivalent in the first vs previous negative biopsy groups with an area under the ROC curve of 0.70 and 0.68, respectively. Unlike serum prostate specific antigen the PCA3 score did not increase with prostate volume. PCA3 assay sensitivity and specificity were equivalent at serum prostate specific antigen less than 4, 4 to 10 and more than 10 ng/ml. A logistic regression algorithm using PCA3, serum prostate specific antigen, prostate volume and digital rectal examination result increased the AUC from 0.69 for PCA3 alone to 0.75 (p = 0.0002). PCA3 is independent of prostate volume, serum prostate specific antigen level and the number of prior biopsies. The quantitative PCA3 score correlated with the probability of positive biopsy. Logistic regression results suggest that the PCA3 score could be incorporated into a nomogram for improved prediction of biopsy outcome. The results of this study provide further evidence that PCA3 is a useful adjunct to current methods for prostate cancer diagnosis.Keywords
This publication has 16 references indexed in Scilit:
- Circulating biomarkers for prostate cancerWorld Journal of Urology, 2007
- Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of CurabilityJNCI Journal of the National Cancer Institute, 2006
- Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention TrialJNCI Journal of the National Cancer Institute, 2006
- Detection of Prostate Cancer and Predicting ProgressionClinical Cancer Research, 2004
- DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate CancerEuropean Urology, 2003
- Screening for prostate cancer with prostate-specific antigen: beware the biasesClinica Chimica Acta; International Journal of Clinical Chemistry, 2001
- Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic DiseaseJAMA, 1998
- THE EFFECT OF PROSTATITIS, URINARY RETENTION, EJACULATION, AND AMBULATION ON THE SERUM PROSTATE-SPECIFIC ANTIGEN CONCENTRATIONUrologic Clinics of North America, 1997
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateThe New England Journal of Medicine, 1987
- An Evaluation of Prostate Specific Antigen in Prostatic CancerJournal of Urology, 1987